Recent Research Analysts’ Ratings Updates for Veracyte (VCYT)

Veracyte (NASDAQ: VCYT) has recently received a number of price target changes and ratings updates:

• 12/29/2025 – Veracyte had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/27/2025 – Veracyte was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 12/22/2025 – Veracyte had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Veracyte had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/13/2025 – Veracyte was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 12/8/2025 – Veracyte had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – Veracyte had its price target raised by analysts at Morgan Stanley from $40.00 to $48.00. They now have an “underweight” rating on the stock.
• 12/1/2025 – Veracyte had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – Veracyte had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – Veracyte had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/16/2025 – Veracyte was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 11/13/2025 – Veracyte had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/11/2025 – Veracyte had its price target raised by analysts at Morgan Stanley from $28.00 to $40.00. They now have an “underweight” rating on the stock.
• 11/8/2025 – Veracyte was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 11/7/2025 – Veracyte was upgraded by analysts at Weiss Ratings from a “sell (d+)” rating to a “hold (c)” rating.
• 11/5/2025 – Veracyte had its price target raised by analysts at UBS Group AG from $42.00 to $48.00. They now have a “buy” rating on the stock.
• 11/5/2025 – Veracyte had its price target raised by analysts at Needham & Company LLC from $41.00 to $44.00. They now have a “buy” rating on the stock.
• 11/5/2025 – Veracyte had its price target raised by analysts at Canaccord Genuity Group Inc. from $40.00 to $43.00. They now have a “hold” rating on the stock.
• 11/5/2025 – Veracyte had its price target raised by analysts at Guggenheim from $40.00 to $45.00. They now have a “buy” rating on the stock.

Insider Transactions at Veracyte

In other Veracyte news, insider John Leite sold 1,278 shares of the company’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $47.51, for a total transaction of $60,717.78. Following the transaction, the insider directly owned 82,113 shares in the company, valued at approximately $3,901,188.63. This represents a 1.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Karin Eastham sold 20,000 shares of the firm’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $45.45, for a total value of $909,000.00. Following the completion of the transaction, the director directly owned 13,554 shares of the company’s stock, valued at $616,029.30. The trade was a 59.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 142,984 shares of company stock valued at $6,282,692 over the last 90 days. Insiders own 1.40% of the company’s stock.

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.